Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>

Ovarian Cancer Videos

Dr. Cosgrove on Selecting a PARP Inhibitor for Maintenance Therapy in Ovarian Cancer
Dr. Cosgrove on Selecting a PARP Inhibitor for Maintenance Therapy in Ovarian Cancer
Casey M. Cosgrove, MD, discusses factors to consider when selecting a PARP inhibitor as maintenance therapy in advanced ovarian cancer.
 
Onclive TV   >   
Potential of Genetic Testing Beyond BRCA1/2 in Ovarian Cancer
Potential of Genetic Testing Beyond BRCA1/2 in Ovarian Cancer
Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer. 
 
Onclive TV   >   
Dr. Backes on Treatment Selection With PARP Inhibitors in Ovarian Cancer
Dr. Backes on Treatment Selection With PARP Inhibitors in Ovarian Cancer
Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses treatment selection with PARP inhibitors in ovarian cancer.
Onclive TV   >   
Dr. Fowler on Considerations for Cytoreductive Surgery in Ovarian Cancer
Dr. Fowler on Considerations for Cytoreductive Surgery in Ovarian Cancer
Jeffrey M. Fowler, MD, discusses factors used to determine whether a patient with advanced ovarian cancer is eligible for primary cytoreductive surgery.
Onclive TV   >   
Dr. O'Malley on Toxicity Profiles of PARP Inhibitors in Ovarian Cancer
Dr. O'Malley on Toxicity Profiles of PARP Inhibitors in Ovarian Cancer
David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer. 
 
Onclive TV   >   
Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice
Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice
OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.
Onclive TV   >   
Dr. Gonzalez-Martin on Rationale for Phase III PRIMA Trial in Advanced Ovarian Cancer
Dr. Gonzalez-Martin on Rationale for Phase III PRIMA Trial in Advanced Ovarian Cancer
Antonio Gonzalez-Martin, MD, discusses the rationale for the phase III PRIMA trial investigating niraparib (Zejula) as maintenance therapy for patients with platinum-sensitive advanced ovarian cancer.
 
Onclive TV   >   
Dr. Coleman on Rationale for Using Veliparib and Chemotherapy in Ovarian Cancer
Dr. Coleman on Rationale for Using Veliparib and Chemotherapy in Ovarian Cancer
Robert L. Coleman, MD, FACOG, FACS, discusses what makes veliparib a unique agent in high-grade serous ovarian cancer.
 
Onclive TV   >   
Dr. Ledermann on Rationale for ARIEL3 Trial in Ovarian Cancer
Dr. Ledermann on Rationale for ARIEL3 Trial in Ovarian Cancer
Jonathan A. Ledermann, MD, discusses the rationale for the randomized, double-blind, placebo-controlled, phase III ARIEL3 trial which explored rucaparib as maintenance therapy in women with high-grade, recurrent ovarian cancer who previously received platinum-based chemotherapy. 
 
Onclive TV   >   
Dr. Holman on Screening for Ovarian Cancer
Dr. Holman on Screening for Ovarian Cancer
Laura L. Holman, MD, discusses screening options for ovarian cancer.
Onclive TV   >   
Next Page >>
Publication Bottom Border
Border Publication
 
x